LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 3 of 15: Cell count and relative growth within biological replicate 3. - Dataset - HMS LINCS Database

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 3 of 15: Cell count and relative growth within biological replicate 3. - Dataset (ID:20239)

Download: Excel (XLSX), Comma-separated (CSV)

<<<<

Select the entities to show:

Small molecules	Cells

|<
<<
Previous
Page 23 of 497
Next
>>
>
551 to 575 of 12420 records
per page:

Cell	Small Molecule	Small Mol Concentration	Small Mol Conc Unit	LJP Library Plate	Replicate	Assay Well	Timepoint	Timepoint Unit	Total Cell Count Before Treatment	Total Cell Count After Treatment	Total Control Cell Count	Relative Cell Count	Relative Growth Rate After Treatment
BT-20	Neratinib	0.12	uM	LJP5	2	A17	72	hr	1097	2721	3769	0.7218	0.6076
BT-20	Neratinib	0.12	uM	LJP5	3	A17	72	hr	1097	2749	3769	0.7293	0.6181
BT-20	Nilotinib	0.12	uM	LJP5	1	N17	72	hr	1097	3967	3769	1.0524	1.0739
BT-20	Nilotinib	0.12	uM	LJP5	2	N17	72	hr	1097	4377	3769	1.1612	1.2273
BT-20	Nilotinib	0.12	uM	LJP5	3	N17	72	hr	1097	3664	3769	0.9720	0.9605
BT-20	Nintedanib	0.12	uM	LJP6	1	H05	72	hr	1097	3145	3769	0.8343	0.7663
BT-20	Nintedanib	0.12	uM	LJP6	2	H05	72	hr	1097	3513	3769	0.9319	0.9040
BT-20	Nintedanib	0.12	uM	LJP6	3	H05	72	hr	1097	3511	3769	0.9314	0.9033
BT-20	NU7441	0.12	uM	LJP5	1	C11	72	hr	1097	3850	3769	1.0213	1.0301
BT-20	NU7441	0.12	uM	LJP5	2	C11	72	hr	1097	3649	3769	0.9680	0.9549
BT-20	NU7441	0.12	uM	LJP5	3	C11	72	hr	1097	3763	3769	0.9983	0.9976
BT-20	Dactolisib	0.12	uM	LJP5	1	M17	72	hr	1097	1192	3769	0.3162	0.0355
BT-20	Dactolisib	0.12	uM	LJP5	2	M17	72	hr	1097	1059	3769	0.2809	-0.0143
BT-20	Dactolisib	0.12	uM	LJP5	3	M17	72	hr	1097	1043	3769	0.2767	-0.0203
BT-20	NVP-TAE684	0.12	uM	LJP6	1	K17	72	hr	1097	3545	3769	0.9404	0.9160
BT-20	NVP-TAE684	0.12	uM	LJP6	2	K17	72	hr	1097	3589	3769	0.9521	0.9324
BT-20	NVP-TAE684	0.12	uM	LJP6	3	K17	72	hr	1097	3905	3769	1.0359	1.0507
BT-20	Palbociclib	0.12	uM	LJP6	1	E17	72	hr	1097	2026	3769	0.5375	0.3476
BT-20	Palbociclib	0.12	uM	LJP6	2	E17	72	hr	1097	1978	3769	0.5247	0.3296
BT-20	Palbociclib	0.12	uM	LJP6	3	E17	72	hr	1097	1873	3769	0.4969	0.2903
BT-20	PD0325901	0.12	uM	LJP5	1	C05	72	hr	1097	3049	3769	0.8089	0.7304
BT-20	PD0325901	0.12	uM	LJP5	2	C05	72	hr	1097	2794	3769	0.7412	0.6349
BT-20	PD0325901	0.12	uM	LJP5	3	C05	72	hr	1097	3440	3769	0.9126	0.8767
BT-20	PD0325901	0.12	uM	LJP6	1	E05	72	hr	1097	3062	3769	0.8123	0.7352
BT-20	PD0325901	0.12	uM	LJP6	2	E05	72	hr	1097	3193	3769	0.8471	0.7843

|<
<<
Previous
Page 23 of 497
Next
>>
>
551 to 575 of 12420 records
per page:

HMS LINCS Project

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 3 of 15: Cell count and relative growth within biological replicate 3. - Dataset (ID:20239)